00:10 , Jun 4, 2019 |  BC Innovations  |  Distillery Techniques

Tool compounds for probing the role of human cGAS in inflammatory diseases

TECHNIQUES CATEGORY: Chemistry TECHNOLOGY: Tool compound Small molecule inhibitors of human cGAS could be used to probe the role of cGAS-dependent signaling in inflammatory diseases. Screening of a compound library followed by optimization of the...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
14:18 , May 20, 2019 |  BC Innovations  |  Distillery Techniques

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling Alterations in RB1 could help predict survival in mCRPC patients treated with Zytiga or Xtandi. In 429 patients with mCRPC, analysis of whole-exome sequencing, gene expression, histopathology, survival and...
22:42 , May 15, 2019 |  BC Extra  |  Clinical News

May 15 Clinical Quick Takes: Principia, Agios, Y-mAbs, Pfizer

Principia gets $30M from Sanofi for Phase IIb MS trial start  Principia Biopharma Inc. (NASDAQ:PRNB) said partner Sanofi (Euronext:SAN; NASDAQ:SNY) began a Phase IIb trial of SAR442168 to treat relapsing multiple sclerosis, triggering a $30...
12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
18:03 , May 2, 2019 |  BC Innovations  |  Translation in Brief

From MSI-high to MSI-higher

A study in Science offers more clues to the consistent but poorly defined link between tumor mutation load and checkpoint inhibitor response. The data could explain why less than half of patients with MSI-high status...
12:54 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

OXPHOS complex V inhibitor to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies identified a benzimidazolinium-based inhibitor of OXPHOS complex V that could help treat glioblastoma. Screening of 200,000 small molecules in primary mouse glioblastoma cells yielded...
21:39 , Apr 24, 2019 |  BC Extra  |  Politics & Policy

Former FDA, CMS heads commend importation, government negotiation to control drug prices

In an editorial published in JAMA , former FDA Commissioner Robert Califf and former CMS Acting Administrator Andrew Slavitt endorsed a wide range of policies to reduce drug costs, including targeted importation, cutting supply chain...
17:09 , Apr 23, 2019 |  BC Innovations  |  Distillery Therapeutics

The iron replacement drug Feraheme as a leukemia therapy

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Patient sample and mouse studies suggest Feraheme ferumoxytol could help treat AML with low ferroportin levels. In primary AML blasts and progenitor cells, levels of ferroportin were...